Travere Therapeutics, Inc. (TVTX): Operating Cash Flow
$37.78M
Year ended 2025-12-31
$92.70M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.78M | n/m | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | -$237.47M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | -$280.02M | n/m | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | -$186.29M | n/m | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | -$14.79M | n/m | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | -$42.74M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$58.21M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$24.96M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $7.40M | n/m | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | -$3.44M | n/m | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | -$1.39M | n/a | 2018-07-06, From 2015-01-01 |
| No annual figure between 2013-12-31 and 2015-12-31. | |||
| 2013-12-31 | -$17.59M | n/m | 2015-07-09, From 2013-01-01 |
| 2012-12-31 | -$2.74M | n/a | 2015-07-09, From 2012-01-01 |
| 2012-02-29 | -$49 | n/m | 2012-05-24, From 2011-03-02 |
| 2011-02-28 | -$689 | n/a | 2012-05-24, From 2010-03-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $37.78M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$445.91M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $55.83M | +440.7% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | -$150.79M | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | -$64.66M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | -$10.31M | n/m |
| Innoviva, Inc. (INVA) | 2025-12-31 | $196.93M | +4.4% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$42.48M | n/m |
Compare TVTX, NATR, BBIO, MIRM side by side · Screen every company in Pharmaceutical Preparations ↗